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Abstract
A novel electronic cell sensor array technology, the real-time cell analysis (RTCA) system, was developed to monitor cell
events. Unlike the conventional methods labeling the target cells with fluorescence, luminescence, or light absorption, the
RTCA system allows for label-free detection of cell processes directly without the incorporation of labels. Here, we used this
new format to measure the cytopathic effect (CPE) of the 2009 influenza A (H1N1) virus and the efficacy of neutralizing
antibodies in human sera to this virus. The real-time dynamic monitoring of CPE was performed on MDCK cell cultures
infected with the H1N1 virus, ranging from 5.50610
2 to 5.50610
7 copies/mL. The resulting CPE kinetic curves were
automatically recorded and were both time and viral load dependent. The CPE kinetics were also distinguishable between
different H1N1 stains, as the onset of CPE induced by the A/Shanghai/37T/2009 H1N1 virus was earlier than that of the A/
Shanghai/143T/2009 H1N1 virus. Furthermore, inhibition of H1N1 virus-induced CPE in the presence of human specific anti-
sera was detected and quantified using the RTCA system. Antibody titers determined using this new neutralization test
correlated well with those obtained independently via the standard hemagglutination inhibition test. Taken together, this
new CPE assay format provided label-free and high-throughput measurement of viral growth and the effect of neutralizing
antibodies, illustrating its potential in influenza vaccine studies.
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Introduction
With the 2009 global outbreak of pandemic influenza, large-scale
vaccination against the new strain of influenza A virus subtype
H1N1 was employed to prevent its spread in China, and numerous
clinical trials were initiated to estimate the antibody responses
elicited with the 2009 influenza A (H1N1) virus vaccine [1,2,3].
However, there is still an urgent need for safer and more convenient
approaches to monitor influenza stains that may cause pandemic
influenza with significant levels of morbidity and mortality. As such,
high throughput neutralization assays are required to quantify
neutralizing antibodies for serodiagnosis during influenza infection
as well as for screening candidate vaccines. The traditional
measurement of influenza virus neutralizing antibodies involves
hemagglutination, immunological procedures, or various methods
for cytopathogenic effect (CPE) identification, such as microscopic,
colorimetric, and fluorometric assays [4,5,6,7]. Nevertheless, these
methods are somewhat labor-intensive, which may increase the risk
of aerosol generation [6,7,8].
Since 2004, a real-time cell analysis (RTCA) system based on
microelectronic biosensor technology was developed to monitor
cell events. The electrode impedance, which is displayed as cell
index (CI) values, is measured to characterize cellular status across
the electronic cell sensor array integrated on the bottom of the
electronic microtiter tissue culture plates (E-Plates) [9,10]. Due to
the the novel electronic cell sensor array technology, the RTCA
system can provide dynamic monitoring of nearly all of the cells
present in the wells without the label molecules. By this means, a
wide range of noninvasive, label-free cell-based assays can be
performed, such as monitoring of cytotoxicity and cell death, stem
cell proliferation, RNA interference, virus-mediated cytopathoge-
nicity, etc. [11,12,13,14]. Here, we report the use of the RTCA
system as a tool for quantifying 2009 H1N1 virus-induced CPE in
Madin-Darby canine kidney (MDCK) cells in real time. As a proof
of concept, this format was used to measure neutralizing
antibodies in pre- and post-immune serum from 21 healthy
individuals who had received the 2009 H1N1 vaccination; the
data were then compared with those obtained by hemagglutina-
tion inhibition tests.
Materials and Methods
Cells
MDCK cells (ATCC, Manassas, VA, USA) were maintained in
complete DMEM supplemented with 10% FBS, 100 U/mL
penicillin, and 100 mg/mL streptomycin (Invitrogen, Carlsbad,
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2. For the virus culture, serum free
DMEM (SFM) supplemented with antibiotics and TPCK-trypsin
(Sigma, St. Louis, MO, USA) was used.
Viruses
The following influenza virus strains were used in this study: A/
Shanghai/37T/2009 (H1N1) (SH37T) (GenBank Accession
No. GQ253489–GQ253496) and A/Shanghai/143T/2009 (H1N1)
(SH143T) (GenBank Accession No. GQ340061–GQ340064,
GQ411905–GQ411907 and GQ411909). SH37T and SH143T
were originally isolated from a 30-year-old and a 24-year-old male
patient hospitalized respectively in late-May and early-June 2009 at
Shanghai Public Health Clinical Center (SHAPHC), China. The two
patients were both imported cases which respectively from Australia
and France, presenting with fever, rhinorrhea, sore throat and cough.
Viruses were grown and titrated in MDCK cells at 35uCw i t h5 %
CO2.
Human sera
The 2009 influenza A (H1N1) vaccine (inactivated split virion)
was produced by the Shanghai Institute of Biological Products,
contained the WHO recommended vaccine virus A/California/
07/2009 NYMC X-179A, and was issued by the U.S. Centre for
Disease Control and Prevention [15,16]. The vaccine was
administered intramuscularly in the upper arm. A total of 21
pre- and post-vaccination serum triples were collected from
healthy adult subjects. Pre-vaccination sera were obtained before
vaccination (S0 samples). Post-vaccination sera were obtained 7
and 21 days later after vaccination (S1 and S2 samples,
respectively). Serum samples were stored at 280uC until required
and were heat-inactivated at 56uC for 30 minutes before use.
Ethics Statement
Written informed consent was obtained from all subjects. The
subjects all confirmed that they understood the study procedures.
The overall study was reviewed and approved by the Ethics
Committee of SHAPHC.
Real-time PCR
Viral nucleic acid was extracted using a High Pure Viral
Nucleic Acid Kit (Roche Applied Sciences, Indianapolis, IN, USA)
according to the manufacturer’s instructions. Purified viral nucleic
acid templates were amplified with real-time PCR using the
Diagnostic Kit for 2009 Influenza A/H1N1 Virus RNA (KHB,
Shanghai, China) in a Mastercycler ep realplex 2.2 real-time PCR
system (Eppendorf, Hamburg, Germany) according to the
manufacturer’s instructions.
Cell proliferation assays
The RTCA system (xCELLigence; Roche Applied Sciences,
Indianapolis, IN, USA) is comprised of four components: an
electronic sensor analyzer, a device station, E-Plates (E-Plate 96),
and a control unit with applied software. The device station was
located inside a tissue culture incubator and could be switched to
any one of the wells of the E-Plate for impedance measurement
using the electronic sensor analyzer. Under control of the control
unit software, the CI values are then derived from the electronic
impedances and graphically represented.
For real-time cell proliferation assays, 50 mL of cell culture
media was added to each well of a 96-well E-Plate to obtain
background readings. Serial two-fold MDCK dilutions from
4.0610
4 to 2.5610
3 cells/well in 100 mL of media were then
seeded into the E-Plate. The E-Plates containing cells were then
incubated for 30 minutes at room temperature and placed on the
RTCA SP/MP station located in a cell culture incubator. The CI
values were measured automatically every 15 minutes.
To determine the optimal TPCK-trypsin concentration, a cell
proliferation assay in SFM containing TPCK-trypsin was
performed. When the cells had reached confluence, the E-Plate
was removed from the RTCA station and washed twice with SFM.
A total of 150 mL of SFM containing TPCK-trypsin at a final
concentration of 10–0.31 mg/mL was added. The E-Plate was
immediately placed back in the station and CI measurements were
subsequently resumed.
Real-time monitoring of virus-induced cytopathogenicity
A total of 1.0610
4 MDCK cells/well was seeded into each well
of an E-Plate. One of two H1N1 strains, SH37T or SH143T, was
10-fold diluted (10
21 to 10
26) in SFM containing 2.5 mg/mL
TPCK-trypsin. Both strains were quantitated by real-time PCR
and adjusted to an identical viral load of 5.50610
8 copies/mL
before dilution. When the CI reached stationary phase after
seeding, the cells were washed with SFM and then infected with
150 mL of the virus series. Wells were mock infected with only
medium as negative controls. After reloading the E-Plate onto the
station, the CI values were measured every 15 minutes for up to
190 hours. Additionally, a colorimetric assay using the cell
proliferation reagent WST-1 (Water soluble tetrazolium salts)
(Roche Applied Sciences, Indianapolis, IN, USA) was also
performed to determine H1N1-induced CPE and titrate the virus
as described previously [6,17]. The assay was based on the
cleavage of tetrazolium to formazan salts by mitochondrial
dehydrogenases of metabolically active cells, resulting in the color
change of the well. Thus the formed formaza dye was quantified
spectrophotometrically and correlated directly to the cell viability.
The ratio of viral load per 50% tissue culture infectious dose
(TCID50) was calculated to determine the number of units
required to produce the specific endpoint [18].
Neutralization test (NT) based on the RTCA system
Dilutions of the H1N1 viruses and the test sera were prepared in
SFM with TPCK-trypsin to a final concentration of 2.5 mg/mL.
The test sera, serially two-fold diluted starting from a dilution of
1:10, were mixed with an equal volume of medium containing
approximately 100 TCID50 of the H1N1 virus. After incubation
at 35uC for 60 min, 150 mL of the serum-virus mixture series was
transferred to triplicate monolayers of MDCK cells in the E-Plates.
Wells containing virus dilutions in the absence of test sera and
wells containing only MDCK cells in SFM were included on each
assay plate as controls. H1N1-induced CPE was then monitored
using the RTCA system (as described above) over 72 hours. The
neutralizing titer was defined as the reciprocal of the lowest
concentration of serum at which the infectivity of 100 TCID50 of
H1N1 was completely neutralized in all the MDCK wells.
Hemagglutination inhibition (HI) test
The HI test was performed according to standard procedures
[19]. The test sera were treated with receptor destroying enzyme
(RDE) (Sigma, St. Louis, MO, USA) to inactivate nonspecific
inhibitors. The sera were then two-fold diluted starting from a
dilution of 1:10. A 1.5% suspension of guinea pig erythrocytes in
PBS and four hemagglutinating units of influenza antigen were used.
Statistical analysis
Statistical analysis was performed using SPSS v17.0 (SPSS,
Chicago, IL, USA) and GraphPad Prism v5.0 (GraphPad
Real-Time Cell Analysis for H1N1 Cytopathogenesis
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(GMTs) were calculated by assigning a titer of 5 to the samples HI
and NT titers below the lower limit of detection (titer ,10). The
Wilcoxon signed rank test was used to calculate p values when
comparing GMTs between paired data. p values of less than 0.05
were regarded as statistically significant. Spearman’s correlation
coefficient was used to calculate the correlation between the NT
and HI test results. R values of more than 0.5 were regarded as
closely related.
Results
Optimization of MDCK cell numbers and trypsin
concentration
To identify the most suitable MDCK cell numbers, a series of
MDCK cell proliferation curves were performed (Figure 1A).
Then the level of 1.0610
4 cells/well was selected, for which
reached the highest CI value during the grow process. As the cells
were in the growth phase or the early stationary phase at 16 to
24 hours after seeding, this period of time was suitable for virus
infection.
Since infection of the influenza virus into MDCK cells in vitro is
promoted by the addition of trypsin to the medium, the TPCK-
trypsin concentration should be optimized. The cell proliferation
of 1.0610
4 MDCK cells/well under different doses of TPCK-
trypsin (Figure 1B) was performed, and the highest TPCK-trypsin
concentration that minimally influenced MDCK cell proliferation
was determined to be 2.5 mg/mL.
2009 H1N1 virus cytopathogenicity profile
Based on the dynamic monitoring of cell proliferation, 1.0610
4
MDCK cells in stationary phase were infected with SH37T or
SH143T at the same viral load of 5.50610
8 copies/mL after
seeding. In the meantime, the presence of CPE was visualized by
microscopic examination (Figure 2A). A decline in CI reflected cell
death as a consequence of H1N1 virus replication (Figure 2B),
while mock-infected cells continued to grow. Parallel WST-1
colorimetric assays were performed to ascertain whether the CIs
correlate with CPE. As shown in Figure 2C, the absorbance values
representing the viable cell population were decreased due to
CPE. These results demonstrated the accurate monitoring of
H1N1-induced CPE using the RTCA system. With the virus load
Figure 1. Dynamic monitoring of MDCK cell proliferation. MDCK cells were seeded in the E-Plates and continuously monitored by measuring
the CI to identify the appropriate cell numbers, TPCK-trypsin concentration, and the time point for addition of virus (i.e., during growth or early
stationary phase). A) Proliferation curves of MDCK cells in cell culture media. B) Proliferation curves of MDCK cells in SFM with TPCK-trypsin. At the
indicated time point the cells were inoculated with different concentrations of virus and TPCK-trypsin.
doi:10.1371/journal.pone.0031965.g001
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about 8 hours, illustrating the clear correlation between the onset
of CPE and the infectious virus load.
Interestingly, although using the same viral load, cells infected
with the different viral strains exhibited different onset times for
CPE and complete cell death. For example, for the 10
21 dilutions,
complete death occurred at 37 hours post-infection for SH37T-
infected cells and at 48 hours for SH143T-infected cells
(Figure 2D). As for the colorimetric TCID50 test, the ratio of
viral load per TCID50 of SH37T was less than that of SH143T
(Table 1), which confirmed the results of the RTCA tests. This
demonstrated that the RTCA test could not only quantify H1N1
viruses-induced CPE, but it also reflected the different infectivity of
the distinct strains.
Real-time neutralization test
Since H1N1-induced CPE was accurately quantified using the
RTCA system, we hypothesized that blocking or delaying CPE by
specific neutralizing antibodies from sera could be quantitated
using the same method. To explore this concept, the neutralization
tests were performed for 21 sera triples using the RTCA System.
Neutralization titers were reported as the reciprocal of the highest
serum dilution that inhibited virus growth by 100%. MDCK cells
on E-Plates were inoculated with serially diluted sera triples that
were pre-incubated with SH37T. Initial serum dilutions of 1:40 for
S0, 1:80 for S1, and 1:160 for S2 were chosen because at higher
serum concentrations virus replication in MDCK cells was clearly
inhibited. A total of 100 TCID50 of virus per assay well was
achieved to reach maximal cell death. H1N1-induced CPE was
monitored in real-time using the RTCA system. The typical results
are illustrated in Figure 3. The CI of S0-treated cells declined to 0
entirely, and the resulting curves appeared similar to virus controls
(Figure 3A), indicated that the S0 dilution above 20-fold could not
inhibit virus growth. However, for the S1 and S2 samples, cell
death was not observed until the serum was diluted to 320- and
1280-fold, respectively, and the resulting curves appeared similar
to control cells (Figure 3B, C). This indicated that the neutralizing
antibody titers in S1 and S2 were 160 and 640, respectively.
Interestingly, the average curve of 1280-fold diluted S2-treated
cells exhibited difference with virus control (Figure 3C), as the
three replicate wells showed distinctly different CI curves
(Figure 3D); one started to decline at about 90 hours, whereas
Figure 2. Real-time monitoring of pH1N1 virus-mediated cytopathogenicity. A) The CPE on MDCK cells infected with SH37T (1:10 diluted)
at 24, 48, and 72 hours post-infection. B) Real-time monitoring of the CPE on MDCK cells infected with SH37T using the RTCA system. The curve was
an average of four independent replicate wells. At the indicated time point the cells were inoculated with different dilutions of virus. C) The
colorimetric assays for the CPE on MDCK cells infected with SH37T (1:10 diluted). OD values at A450 obtained at 24, 48, and 72 hours post-infection
are shown. Error bars indicate standard deviation. D) Difference in CPE kinetic patterns between SH37T and SH143T with the same infectious vial load
of 5.50610
7 copies/mL. The plotted lines indicate the different time points when the CI declined to 0 between stains.
doi:10.1371/journal.pone.0031965.g002
Table 1. TCID50, viral load, and the ratio viral load per TCID50
of two H1N1 stains.
Stain Viral load TCID50 Viral load/TCID50
A/Shanghai/37T/2009
(H1N1)
1.59610
9 10
3.5 4.97610
5
A/Shanghai/143T/2009
(H1N1)
5.50610
8 10
2.9 6.88610
5
doi:10.1371/journal.pone.0031965.t001
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the three wells treated with 1280-fold diluted S2, virus in two wells
was neutralized completely but the rest one was not. So the finally
showed average curve actually resulted from a partial neutraliza-
tion pattern which was different from those of virus control and
complete neutralization wells.
Comparison of the real-time NT and HI test
A total of 21 pre- and post-vaccination sera triples were
collected and tested by real-time NT and HI tests (Table S1).
Geometric mean pre- and post-vaccination titers (GMT), as
determined by NT and HI tests, and the number of serum pairs
exhibiting a significant increase in antibody titers ($4-fold) were
calculated (Table 2). The mean NT titer increase was 4-fold (range
1–16) at day 7 and 13-fold (range 2–64) at day 21 after
vaccination, while the mean HI titer increase was 4-fold (range
1–16) and 9-fold (range 2–64). The rise in antibody levels between
the pre- and post-vaccination sera is illustrated in Figure 4. Almost
all of the 21 subjects exhibited significantly increased antibody
titers to the H1N1 virus after vaccination, as determined by both
the NT and HI test. When the pre- and post-vaccination titers
obtained by HI or NT were compared to each other, there was a
statistically significant difference (p,0.05, Wilcoxon signed rank
test) (Figure 4A, B). The real-time NT and HI antibody titers
showed a close correlation (Spearman’s correlation coefficient,
r=0.78, p,0.01; Figure 4C). Furthermore, the magnitude of the
antibody response to the vaccine was calculated as the maximum
difference between the titer at day 21 and the baseline titer (day 0)
for both the NT and HI test (Figure 4D). There was no difference
in the mean antibody response measured by NT versus the HI test
(p.0.05, Wilcoxon signed rank test). As a consequence, the NT
assessed using the RTCA system was in good agreement with the
HI test. This indicated that the RTCA system could be used to
accurately quantify antibody titers.
Discussion
With the emergence of the 2009 influenza pandemic,
development of an effective vaccine became critical for the
prevention and clearance of influenza virus infections. To evaluate
seasonal or pandemic candidate vaccines, a sensitive, specific, and
reproducible serological method is necessary to measure the
antibody response elicited with a candidate vaccine against wild-
type viruses. In this study, we developed a novel real-time method
for measuring virus-induced CPE and evaluating the efficacy of
neutralizing antibodies using electronic impedance biosensor-
based RTCA technology. The RTCA system is based on
integrated microelectronic sensor arrays, is non-invasive, and
provides kinetic data regarding the dynamic nature of the cellular
response to certain challenges, such as drug treatments [20],
growth factor stimulation [21], analysis of cytotoxic composite
components [22], and virus-induced cytopathogenesis [14].
In this report, this new assay was used to monitor cytolysis
induced by H1N1 viral proliferation. Virus-induced CPE kinetic
curves could be used to differentiate between different infectious
amounts of the same strain as well as to distinguish the infection
kinetics of different H1N1 strains. The two strains, SH37T and
SH143T, were isolated respectively from two hospitalized patients
in SHAPHC received diagnostic of 2009 H1N1 infection at May
2009. While the clinical patterns were essentially similar, these
strains revealed different kinetics of viral infection. The time points
for both the onset of CPE and complete cell death of SH143T-
infected cells were delayed about 10 hours compared with those of
SH37T-infected cells. Because an identical viral load was used,
SH37T appeared to have a greater infectivity than SH143T.
Figure 3. Typical results of real-time neutralization tests against SH37T. CPE kinetic patterns of MDCK cells inoculated with 100 TCID50
virus incubated with a series dilution of sera samples. Antibody titers were calculated as a function of CI with a sequential dilution series of S0 (A), S1
(B), and S2 (C). The curve was an average of three independent replicate wells. At the indicated time point the cells were inoculated with the serial
serum-virus mixture. Three replicate wells of 1280-fold diluted S2 treated cells showed different curves (D). Cell control: MDCK cells only; virus control:
absence of test sera.
doi:10.1371/journal.pone.0031965.g003
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capacity of replication and infectivity on MDCK cell culture. It
was deserved to utilize complementary genetic approaches to
define the role of specific viral genes and proteins underlying the
phenotypes. Using real-time analysis, Ying Fang et al. [14]
generated a mathematical model simulating the CI response to
different virus species, through which the virus replication
doubling time, virus number threshold for host cell death, and
average time to cell death was determined. Meanwhile, the RTCA
assay could directly distinguish different strains of the same virus
on the basis of our results. For quantitation of virulence, it is
necessary to compare different viral stains, determine the number
of infectious units required to produce the specific endpoint [18].
Taken together, it is indicated that the RTCA system may provide
a feasible in vitro format for assessment of virulence by monitoring
CPE kinetics in future investigations of the influenza virus. It may
further help to elucidate the relationship between genetic
alterations and virulent variations for virological surveillance of
influenza.
Since virus-induced CPE could be quantitatively monitored
using the RTCA system, we also performed a real-time
neutralization assay for measuring H1N1-specific antibodies in
Figure 4. Antibody titers in 21 pre- and post-vaccination sera triples measured by real-time NT and HI tests. A, B) There was a
statistically significant difference (p,0.01, Wilcoxon signed rank test) when the pre- and post-vaccination titers obtained by real-time NT (A) or HI test
(B) were compared to each other. C) The NT and HI antibody titers correlated well (Spearman’s correlation r=0.78, p,0.01). D) Antibody titers on day
21 after vaccination relative to baseline (day 0). There was no significant difference (p.0.05, Wilcoxon signed rank test) in the results among the NT
versus HI tests. Low responders: no increase above twofold; high responders: fourfold or more above baseline.
doi:10.1371/journal.pone.0031965.g004
Table 2. Geometric mean titers (GMT), titer ranges, and significant titer rises observed from 21 pre- and post-vaccination serum
triples.
Test GMT Titer ranges
Number of significant
antibody rises (%) (S2/S0 $4)
S0 S1 S2 S0 S1 S2
NT 29 104 365 20–80 40–320 40–1280 17(81%)
HI 20 77 177 ,10–80 ,10–640 20–640 18(86%)
doi:10.1371/journal.pone.0031965.t002
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as a standard for epidemiological and immunological studies, as
well as for measuring the efficacy of influenza vaccines and
potency of neutralizing antibodies, this new assay was evaluated
against the standard HI test on a panel of sera collected from adult
donors before and after immunization with the H1N1 vaccine.
Both assays showed an obvious increase in neutralizing antibodies
in the test sera at 3 weeks post-vaccination, and there was a good
agreement between the HI and NT antibody titers. However,
higher antibody titers were detected using the RTCA-based NT
method, indicating the higher sensitivity of this assay. This may
have been due to the difference between the CPE-based and HA-
based assays, which had been observed in previous reports [23,24].
Such functional quantitation may provide a valuable platform for
serological diagnosis, immunological study, or evaluation of
vaccines for influenza.
An HI titer of 1:40 is commonly recognized as representing
protective immunity. Our results revealed 30% of the HI titers in
the pre-vaccination sera were equal to 1:40, and two were even
higher (data not shown). The first H1N1 case was identified in
May 2009 in Shanghai, and population-wide vaccination followed
in October 2009. Hence, widespread exposure to H1N1 in the
society may have caused the higher antibody titers in the donors
detected here. In addition, other reports have suggested that serum
cross-reactive antibody responses to H1N1 occurred after
vaccination with seasonal influenza vaccine and that this also
existed in the population during the pre-pandemic period
[25,26,27].
In many settings influenza is recognized as a major cause of
disease and death worldwide, which is the first infectious disease
with global surveillance. Not the 2009 Influenza A (H1N1) Virus
but other concomitant seasonal or highly pathogenic avian
influenza viruses have posed considerable threads to public health.
Global surveillance and annual vaccination are both of the key
strategies and measures for the prevention and control of
influenza. Apart from the evaluation of vaccine immunogenicity,
the RTCA assay we described here can be used as a fundamental
tool in the virological surveillance of influenza.
Assays with 2009 Influenza A (H1N1) Virus and other seasonal
influenza viruses are performed biosafety level-2 (BSL-2), whereas
assays with replication competent wide-type H5N1 and other
potentially pandemic viruses must be performed under biosafety
level-3 (BSL-3) containment, requiring convenient and labor-
saving assays to minimize the hands-on steps. Conventional virus
quantification and neutralization tests for influenza viruses require
several manipulations, which are laborious and rather slow.
However, the RTCA assay provides data continuously and
automatically in a remote manner after the initial virus
inoculation, which could save on time and labor for assay
development and also decrease the risk of aerosol generation. With
the few hands-on manipulations required, this new format allows
for label-free, high throughput, and automatic testing, and could
easily be adapted to assays under BSL-3 conditions.
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